Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of obexelimab in systemic lupus erythematosus
2024-510584-37-00Phase 2Authorised
- Sponsor
- Zenas BioPharma
- Start
- Oct 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Obexelimab + background standard of care with Placebo + background standard of care (2 arms). Primary endpoint: BICLA response at Week 24. Planned start Oct 2024; status: authorised.
02
Drugs
obexelimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2024-510584-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510584-37-00.